Role of Tranexamic acid and Hemocoagulase in axillary lymph node dissection: a double blinded superiority trial
Phase 3
Completed
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2022/04/041616
- Lead Sponsor
- Harshit Verma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 63
Inclusion Criteria
All breast cancer patients who will undergo axillary lymph node dissection.
Exclusion Criteria
Patient who has received prior radiation therapy to the axilla.
Patients with history of known allergy to drugs used.
Patients who are known case of clotting disorder or active thromboembolic disease.
Patients pregnant or lactating.
Patients with past or current history of lymphedema of limb on the affected side.
Patients not willing to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure and compare the cumulative axillary drain output in breast cancer patients undergoing axillary lymph node dissection treated with Tranexamic acid plus Hemocoagulase versus placebo.Timepoint: 30 days
- Secondary Outcome Measures
Name Time Method Days after axillary drain is removedTimepoint: Till axillary drain is in situ;Frequency and volume of axillary seroma aspirationsTimepoint: till 30 days from surgery;Incidence of surgical site infectionTimepoint: till 30 days from surgery